EXOTIC PET BREEDING BUSINESS PLAN
I. Executive Summary
Company Description
The company name references its Miami roots and conservation-focused mission, signaling provenance and ethical breeding practices. Based in Miami, Florida, the business operates in the exotic pet breeding sector and serves the professional hobbyist market in the United States. It produces captive-bred reptiles and select small mammals, each sold with genetic transparency, comprehensive health documentation, and traceable lineage. Core activities include closed-loop facility breeding, licensed veterinary oversight, pedigree tracking, and controlled husbandry protocols designed to reduce disease and preserve genetics. One-liner: Ethical, traceable captive breeding for serious hobbyists.
The leadership team combines herpetology, genetics, and facility management to run a state-of-the-art, biosecure breeding operation that prioritizes welfare and reproducible outcomes. What sets the business apart is its science-based protocols, rigorous health records, and facility-level biosecurity that together lower mortality and post-sale issues for buyers. Target customers are U.S.-based professional hobbyists, specialty retailers, and accredited institutions seeking high-quality, documented stock. Short-term goals focus on operational validation and regional market entry; long-term goals target becoming the U.S. gold standard for professional exotic animal breeding. One-liner: Scale proven, welfare-first breeding into a national reference brand.
Problem
Enthusiasts and professional hobbyists face a U.S. supply market dominated by hobbyist breeders and importers who frequently sell animals with unknown genetics, inconsistent care, and limited health documentation—resulting in high mortality rates, long-term welfare issues, and buyers lacking the documented lineage and health guarantees common in other high-value animal industries.
There is a clear market gap: a shortage of professional, transparent, science-driven breeders who follow standardized husbandry. Based in Miami, Florida, our closed-loop facility and team of herpetology, genetics, and facility management experts address that gap by prioritizing genetic transparency, meticulous husbandry, and comprehensive health documentation—setting a new standard for ethical, reliable captive-bred exotic animals for professional hobbyists.
Solution
The exotic pet market currently lacks transparency and consistent health standards because it relies on wild-caught imports and hobbyist breeders, creating high mortality and disease risks for collectors. Our business provides a science-based, professional breeding program that manages the full animal lifecycle in a closed-loop facility and delivers captive-bred specimens with verified digital lineage, health records, post-purchase support, and health guarantees.
One-liner: We supply documented, captive-bred specimens that reduce mortality, disease, and legal risk for high-end collectors.
Mission Statement
Our mission is to lead the exotic pet breeding industry through scientific excellence, ethical husbandry, and full transparency, producing the healthiest, genetically sound captive-bred animals for enthusiasts and collectors worldwide. We commit to eliminating reliance on unverified and wild-caught sources by setting clear welfare standards and sharing verifiable health and lineage data. We empower customers with practical care guidance and ongoing support so animals thrive in long-term captivity.
Key Success Factors
Success depends on biosecurity, genetics, scale, regulation, and trust with collectors.
-
Maintain biosecure operations to cut juvenile mortality from 15.0% to 4.0% over ten years.
-
Employ expert management and a dedicated geneticist to produce rare morphs that command premium prices.
-
Scale breeding capacity from 100 to 600 females to drive predictable revenue growth.
-
Ensure strong regulatory compliance and industry advocacy to protect interstate commerce.
-
Provide documented lineage and health guarantees to secure repeat business from high-value collectors.
Financial Summary
Quick snapshot: launch 2026 with front-loaded investment, breakeven in Nov 2029, positive EBITDA $196,000 by 2030 and $3,208,000 by 2035.
Ratio | 2026 | 2027 | 2028 |
Projected Revenue | N/A | N/A | N/A |
Projected EBITDA | -$393,000 | -$351,000 | -$248,000 |
Expected ROI | IRR 0.02% | IRR 0.02% | IRR 0.02% |
Financial requirements: initial capex and working capital through 2026–2029 to cover minimum cash shortfall (minimum cash -$728,000 in Nov-29); anticipated return: project IRR 0.02% and long-term ROE 7.47% by 2035.
Outlook: the model moves from initial losses to breakeven in Nov‑2029 and scalable profitability thereafter.
Funding Requirements
We plan to raise $825,000 to cover capital expenditure, working capital, and launch costs through breakeven (expected Nov-29, 2029).
Categories | Amount, USD |
Facility & Equipment (CapEx, 2026) | $425,000 |
Working capital (operations pre-breakeven) | $375,000 |
Marketing & Sales | $15,000 |
Contingency / Legal & Licensing | $10,000 |
Total funding required | $825,000 |